The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Subscribe To Our Newsletter & Stay Updated
